A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Trial Profile

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 01 Aug 2017 Planned primary completion date changed from 31 Oct 2017 to 6 Dec 2018.
    • 25 Jun 2017 Results assessing impact of Venetoclax on health related quality of life based on a second interim analysis presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results of interim analysis evaluating an impact on health related quality of life (HRQoL) presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top